MALT1: The Dual Domains Drive Resistance to Immune Checkpoint Inhibitors

Haoze Xie; Jie Zhang; Yicheng Chen

doi:10.1002/mef2.70023

MEDCOMM - Future Medicine ›› 2025, Vol. 4 ›› Issue (2) : e70023 DOI: 10.1002/mef2.70023

HIGHLIGHT

MALT1: The Dual Domains Drive Resistance to Immune Checkpoint Inhibitors

Author information +

History +

PDF

Cite this article

Download citation ▾

Haoze Xie, Jie Zhang, Yicheng Chen. MALT1: The Dual Domains Drive Resistance to Immune Checkpoint Inhibitors. MEDCOMM - Future Medicine, 2025, 4(2): e70023 DOI:10.1002/mef2.70023

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Y. Tao, C. Tian, S. Qi, et al., “Targeting Both Death and Paracaspase Domains of MALT1 With Antisense Oligonucleotides Overcomes Resistance to Immune-Checkpoint Inhibitors,” Nature Cancer 6 (2025): 702–717.

[2]	G. Oliveira and C. J. Wu, “Dynamics and Specificities of T Cells in Cancer Immunotherapy,” Nature Reviews Cancer 23, no. 5 (2023): 295–316.

[3]	A. Lyu, Z. Fan, M. Clark, et al., “Evolution of Myeloid-Mediated Immunotherapy Resistance in Prostate Cancer,” Nature 637, no. 8048 (2025): 1207–1217.

[4]	X. Xiang, J. Wang, D. Lu, and X. Xu, “Targeting Tumor-Associated Macrophages to Synergize Tumor Immunotherapy,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 75.

[5]	T. J. O'Neill, M. J. Tofaute, and D. Krappmann, “Function and Targeting of MALT1 Paracaspase in Cancer,” Cancer Treatment Reviews 117 (2023): 102568.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).